- Details
- Neil Bander joins Charles Ryan providing a historical perspective on radioligand therapy and the history of prostate-specific membrane antigen (PSMA) for prostate cancer treatment. Dr. Bander recounts his early work in radioligand therapy and how it has developed over the past two decades before discussing the current ongoing trials highlighting a single ascending dose trial and a multiple dose tr...
|
- Details
- Neal Shore and Jason Efstathiou join Alicia Morgans at APCCC 2022 to discuss the current landscape in PSMA PET imaging. Drs Shore and Efstathiou share their thoughts on the agents they are using and the impacts of these new developments in imaging on staging and prognostication. Biographies: Jason Efstathiou, MD, Radiation Oncologist Professor of Radiation Oncology, Harvard Medical School, Vice-Ch...
|
- Details
- Phillip Kuo joins Alicia Morgans to discuss recent findings in a VISION sub-study. Dr. Kuo explains how this post-hoc exploratory analysis of the PSMA PET scans that were done for the VISION trial resulted in a better understanding of which patients are likely to respond better to treatment with lutetium-PSMA-617. Biographies: Phillip H. Kuo, MD, Ph.D., Professor of Medical Imaging, Medicine and B...
|
- Details
- Phillip Koo is joined by Joseph Osborne to provide a nuclear radiologist's perspective on the equity in prostate cancer clinical trials. Dr. Osborne focuses his talk on three different aspects of clinical trial equity for prostate cancer: Progress, Evolution, and Goals. He also details the Rad Health Equity Lab, created at Weill Cornell to improve access to radiology and bring awareness to health...
|
- Details
- Michael Morris joins Alicia Morgans to discuss the clinical implementation of Pluvicto™ (177Lu-PSMA-617) in a way that ensures equity to all patients, regardless of the many factors that could disrupt access. They discuss equity of distribution to all those patients who need it and the availability of PSMA PET scans. Biographies: Michael Morris, MD, Medical Oncologist Clinical Director, Genitourin...
|
- Details
- Oliver Sartor joins Phillip Koo to discuss the United State FDA approval of Pluvicto™ (177Lu-PSMA-617) as the first targeted radioligand therapy for the treatment of PSMA positive metastatic castration-resistant prostate cancer (mCRPC). They discuss currently enrolling in clinical trials with Pluvicto in the pre-chemotherapy treated mCRPC patient population. They look further into the future discu...
|
- Details
- Drs Charles Ryan and Alicia Morgans discuss the approval of Pluvicto TM (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617). Pluvicto was approved based on the pivotal Phase III VISION trial which evaluated men who had post androgen receptor pathway inhibitor therapy and post docetaxel or docetaxel and cabazitaxel chemotherapy, who were randomized to a protocol-defined...
|
- Details
- PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Module 1 15 minutes: Radionuclide Targeted Treatment in Progressing Metastatic Prostate Cancer - Presented by Michael Hofman, MBBS (Hons), FRACP, FAANMS, FICIS 20 minutes: Discussion Moderators Phillip Koo, MD, Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS. Biographies: Professor Michael Hofman, MBBS (Hons), FRACP, FAANMS, FICIS...
|
- Details
- PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Module 2 12 minutes: PSMA-PET Diagnostic Imaging in Prostate Cancer - Presented by Thomas Hope, MD Module 3 16 minutes: PSMA as a Therapeutic Target in Progressing Prostate Cancer - Presented by Johannes Czernin, MD 22 minutes: Discussion moderators Phillip Koo, MD, Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS. Biographies: Joh...
|
- Details
- PSMA Targeted Therapies in Progressive Metastatic Prostate Cancer Module 4 10 minutes: Treatment considerations following 177Lu-PSMA - Presented by Scott Tagawa, MD, MS, FACP 17 minutes: PSMA Imaging: A Necessary Gateway for PSMA-Directed Therapy? - Presented by Michael Morris, MD 24 minutes: Discussion Moderators Phillip Koo, MD, Alicia Morgans, MD, MPH, and Neal Shore, MD, FACS. Biographies: Sco...
|
